Recent News

• 06.03.2025 - BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
• 05.28.2025 - BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
• 05.12.2025 - BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
• 03.27.2025 - BeyondSpring Files 2024 Annual Report on Form 10-K
• 03.27.2025 - BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

Recent Filings

• 05.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.12.2025 - 8-K Current report
• 05.12.2025 - EX-99.1 EX-99.1
• 04.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.23.2025 - 4 Statement of changes in beneficial ownership of securities